您要查找的是不是：
- The primary end point was fatal or nonfatal stroke. 主要终点是致死或非致死的卒中。
- The observer-blinded primary end point was the change in absolute pVO 2. 观察者盲法的主要终点为绝对峰值耗氧量的变化。
- The primary end point was the percentage of patients who experienced virologic failure. 主要终点则为出现病毒失败患者的百分率。
- The primary end point was time to the composite of a doubling of the serum creatinine, ESRD, or death. 主要终点是血清血清肌酸酐增加两倍，终末期肾病，或者死亡。
- The primary end point were achieved in 90% of ETV treated patients versus 69% of LVD treated patients(P<0.0001). 经过48周的治疗;到达主要疗效终点者;ETV组为90%25;LVD组仅69%25(P<0.;0001)。
- Both groups underwent hyperolemic therapy.The primary end point was the preention of hyponatremia. 两组都接受扩容治疗，治疗主要是防止低钠血症。
- A composite of death, myocardial infarction, stroke, and hospital admission for congestive heart failure (not involving renal replacement therapy) was the primary end point. 结果测定：死亡，心肌梗塞，中风以及因充血性心衰入院（不包含肾脏替代治疗）为初级试验终点。
- The primary end point was the incidence of definite/probable early, subacute, and late stent thrombosis at 6-month follow-up. 在6个月的随访中主要终点是确诊的或者可能早期的、亚急性的和晚期的支架血栓形成的发生。
- Higher intrinsic (unpaced) HR was associated with greater risk of achieving the primary end point of death or heart failure hospitalization (P<0.001). 结果发现非起搏心率较高的患者出现死亡或心衰住院等主要终点的风险更高（p<0.;001）。
- The primary end point was disease exacerbation, defined as a Mayo Clinic clinical symptom score of 5 or more and an increase of 1 point or more in the Mayo Clinic flexible sigmoidoscopy score. 试验的终点以病况的恶化程度为依据，并定义为梅约医学中心临床症状分数5以上，及梅约软式乙状结肠镜检评分增加1分。
- Primary end points were the proportion of patients experiencing at least 1 relapse at 12, 24, and 36 months. 治疗的截至点为在12、24和36个月中患者至少经历了一次复发。
- In an analysis including all reported primary end points, the hazard ratio (rosiglitazone regimens s. others) was 1.11 (95% confidence interal, 0.93 to 1.32). 对所有报告病例的分析中，主要终点事件风险率（罗格列酮对其它药物）为1.;11(95%25置信区间，0
- MAIN OUTCOME MEASURES: Primary end points were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease. 主要结果评价：主要终点是动脉粥样硬化事件，包括致命或者非致命缺血性心脏病、致命或者非致命卒中以及周围动脉病。
- Represents an end point for an infrared connection. 表示红外连接的终结点。
- Unable to remove end point binding. 无法删除终结点绑定。
- Quality of life (QOL) was a secondary end point. 生活质量(QOL)为次级试验终点。
- A total of 217 patients in the rosiglitazone group and 202 patients in the control group had the adjudicated primary end point (hazard ratio, 1.08; 在217例罗格列酮治疗组患者和202例对照组患者的总的例数基础上判断主要终点（危险率，1.;08;
- Results: The primary end point occurred in 5% of patients in the atorvastatin arm and in 17% of those in the placebo arm (p = 0.01); 结果：主要终点发生率在阿托伐他汀组为5%25，安慰剂组为17%25(p=0.;01)；
- The ending point is the last point in the sequence. 终结点是该序列中的最后一点。
- The starting or ending point of the range. 范围的开始点或结束点。
